NGN-101 / Neurogene - LARVOL DELTA

CLN5-200: Gene Therapy Study for Children With CLN5 Batten Disease (clinicaltrials.gov) - P1/2 | N=6 | Active, not recruiting | Sponsor: Neurogene Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Gene therapy • CNS Disorders • Gene Therapies